CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12. Dezember 2024 07:00 ET
|
CervoMed Inc.
BOSTON, Dec. 12, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO) (the “Company”), a clinical stage company focused on developing treatments for age-related neurologic disorders, today...
CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies
10. Dezember 2024 07:00 ET
|
CervoMed Inc.
—Neflamapimod did not demonstrate statistically significant effects versus placebo on primary and secondary endpoints at 16 weeks— —Favorable safety and tolerability results with no new safety signal...
CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia
27. November 2024 07:00 ET
|
CervoMed Inc.
Designation underscores significant unmet need in frontotemporal dementia and the potential role of neflamapimod in multiple neurologic disorders On track to report topline data from the RewinD-LB...
CervoMed Announces Key Senior Leadership Appointments
13. November 2024 08:00 ET
|
CervoMed Inc.
BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today reported two senior...
CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
12. November 2024 07:00 ET
|
CervoMed Inc.
- Reported last patient, last visit in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with early-stage dementia with Lewy bodies (DLB) in October 2024; topline data expected...
CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup
08. November 2024 09:55 ET
|
CervoMed Inc.
The Prix Galien USA Best Startup category recognizes outstanding innovation by therapeutics-focused life science companies that have not yet received their first product approval The award to...
CervoMed to Participate in Upcoming Investor Conferences
07. November 2024 08:30 ET
|
CervoMed Inc.
BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that the...
CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
04. November 2024 08:00 ET
|
CervoMed Inc.
Data from the AscenD-LB Phase 2a trial in DLB confirm recent scientific literature indicating that plasma glial fibrillary acid protein (GFAP) is a robust measure of neurodegenerative disease activity...
CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference
29. Oktober 2024 08:00 ET
|
CervoMed Inc.
Topline data from the RewinD-LB Phase 2b study on track for December 2024 Detailed safety and efficacy data from RewinD-LB Phase 2b study to be featured in an oral presentation at the ILBDC...
CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB)
15. Oktober 2024 08:00 ET
|
CervoMed Inc.
• On track to report topline data from the Phase 2b trial in December 2024 • Neflamapimod has the potential to restore function and improve cognitive and motor functions in DLB patients • 96% of...